Autologous Cell Therapy Market Size, Share, Trends, and Growth Outlook

Autologous Cell Therapy Market is estimated to increase at a growth rate of 19.8% CAGR over the forecast period from 2024 to 2030.

 

The Autologous Cell Therapy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Therapy , Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies), By Application (Oncology, Musculoskeletal Disorder, Blood Disorder, Autoimmune Disease, Others), By Source (Bone Marrow, Epidermis, Others), By End-User (Hospitals, Research Centers, Others).

 

An Introduction to Autologous Cell Therapy Market in 2024

The Autologous Cell Therapy market in 2024 focuses on harnessing the regenerative potential of a patient's own cells to treat a wide range of diseases and conditions, offering personalized therapeutic solutions that minimize the risk of rejection and adverse immune reactions. Autologous cell therapies involve harvesting, isolating, and expanding cells from a patient's own tissues, such as bone marrow, adipose tissue, or peripheral blood, and re-administering them to promote tissue repair, modulate immune responses, or deliver therapeutic payloads. From stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy to autologous mesenchymal stromal cell (MSC) treatments, autologous cell therapies hold promise for addressing unmet medical needs in areas such as oncology, autoimmune disorders, and degenerative diseases. As research advances, manufacturing processes evolve, and clinical trials demonstrate safety and efficacy, the autologous cell therapy market continues to grow and diversify, offering new hope and therapeutic options for patients worldwide.

Autologous Cell Therapy Market Trend: Advancements in Cell Therapy Technologies and Techniques

A prominent trend in the Autologous Cell Therapy market is the continuous advancements in cell therapy technologies and techniques. Researchers and biotechnology companies are constantly innovating to improve the efficacy, safety, and scalability of autologous cell therapies. This includes developments in cell isolation, expansion, manipulation, and delivery methods, as well as the incorporation of gene editing and tissue engineering approaches. These advancements are driving the evolution of personalized medicine and expanding the therapeutic potential of autologous cell therapies across various medical indications.

Autologous Cell Therapy Market Driver: Growing Demand for Regenerative Medicine Solutions

The growing demand for regenerative medicine solutions is a significant driver for the Autologous Cell Therapy market. Autologous cell therapies hold promise for treating a wide range of degenerative and chronic diseases, including cardiovascular disorders, neurological conditions, orthopedic injuries, and autoimmune disorders. With an aging population and increasing prevalence of chronic diseases worldwide, there is a heightened need for innovative therapies that can regenerate and repair damaged tissues and organs. Autologous cell therapies offer the advantage of utilizing a patient's own cells, minimizing the risk of immune rejection and potentially providing more durable and personalized treatment outcomes.

Autologous Cell Therapy Market Opportunity: Expansion of Cell Therapy Manufacturing and Commercialization

One potential opportunity in the Autologous Cell Therapy market lies in the expansion of cell therapy manufacturing and commercialization capabilities. As the field of cell therapy continues to advance, there is a growing need for scalable and cost-effective manufacturing processes to meet the demand for autologous cell-based treatments. Streamlining manufacturing workflows, optimizing cell production techniques, and implementing automation technologies can help reduce manufacturing costs, improve product consistency, and accelerate the commercialization of autologous cell therapies. Additionally, establishing robust supply chain logistics and regulatory frameworks will be essential for ensuring the safe and efficient delivery of autologous cell therapies to patients globally. This presents an opportunity for investment in infrastructure, partnerships, and regulatory strategies to support the scalability and commercial success of autologous cell therapy products.

 

Autologous Cell Therapy Market Segmentation

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

 

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

 

By Source

Bone Marrow

Epidermis

Others

 

By End-User

Hospitals

Research Centers

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Autologous Cell Therapy Market Companies

Bayer AG

BrainStorm Cell Therapeutics

Daiichi Sankyo Co. Ltd

Holostem Terapie Avanzate S.r.l.

Lineage Cell Therapeutics Inc

Opexa Therapeutics

Pharmicell Co. Inc

Sangamo Therapeutics

Sumitomo Chemical Co. Ltd

Takeda Pharmaceutical Co. Ltd

Vericel Corp

*- List Not Exhaustive

 

Reasons to Buy the Autologous Cell Therapy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Autologous Cell Therapy Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Autologous Cell Therapy Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Autologous Cell Therapy Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Autologous Cell Therapy Market Size Outlook, $ Million, 2021 to 2030

3.2 Autologous Cell Therapy Market Outlook by Type, $ Million, 2021 to 2030

3.3 Autologous Cell Therapy Market Outlook by Product, $ Million, 2021 to 2030

3.4 Autologous Cell Therapy Market Outlook by Application, $ Million, 2021 to 2030

3.5 Autologous Cell Therapy Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Autologous Cell Therapy Market Industry

4.2 Key Market Trends in Autologous Cell Therapy Market Industry

4.3 Potential Opportunities in Autologous Cell Therapy Market Industry

4.4 Key Challenges in Autologous Cell Therapy Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Autologous Cell Therapy Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Autologous Cell Therapy Market Outlook By Segments

7.1 Autologous Cell Therapy Market Outlook by Segments

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

8 North America Autologous Cell Therapy Market Analysis And Outlook To 2030

8.1 Introduction to North America Autologous Cell Therapy Markets in 2024

8.2 North America Autologous Cell Therapy Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Autologous Cell Therapy Market size Outlook by Segments, 2021-2030

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

9 Europe Autologous Cell Therapy Market Analysis And Outlook To 2030

9.1 Introduction to Europe Autologous Cell Therapy Markets in 2024

9.2 Europe Autologous Cell Therapy Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Autologous Cell Therapy Market Size Outlook By Segments, 2021-2030

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

10 Asia Pacific Autologous Cell Therapy Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Autologous Cell Therapy Markets in 2024

10.2 Asia Pacific Autologous Cell Therapy Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Autologous Cell Therapy Market size Outlook by Segments, 2021-2030

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

11 South America Autologous Cell Therapy Market Analysis And Outlook To 2030

11.1 Introduction to South America Autologous Cell Therapy Markets in 2024

11.2 South America Autologous Cell Therapy Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Autologous Cell Therapy Market size Outlook by Segments, 2021-2030

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

12 Middle East And Africa Autologous Cell Therapy Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Autologous Cell Therapy Markets in 2024

12.2 Middle East and Africa Autologous Cell Therapy Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Autologous Cell Therapy Market size Outlook by Segments, 2021-2030

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

By Source

Bone Marrow

Epidermis

Others

By End-User

Hospitals

Research Centers

Others

 

13 Company Profiles

13.1 Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Bayer AG

BrainStorm Cell Therapeutics

Daiichi Sankyo Co. Ltd

Holostem Terapie Avanzate S.r.l.

Lineage Cell Therapeutics Inc

Opexa Therapeutics

Pharmicell Co. Inc

Sangamo Therapeutics

Sumitomo Chemical Co. Ltd

Takeda Pharmaceutical Co. Ltd

Vericel Corp

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Autologous Cell Therapy Market Segmentation

By Therapy

Autologous Stem Cell Therapy

Autologous Cellular Immunotherapies

 

By Application

Oncology

Musculoskeletal Disorder

Blood Disorder

Autoimmune Disease

Others

 

By Source

Bone Marrow

Epidermis

Others

 

By End-User

Hospitals

Research Centers

Others

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)